Alzheimer's disease (AD) should be regarded as a degenerative metabolic disease caused
by brain insulin resistance and deficiency, and overlapping with the molecular, biochemical …

Introduced less than two decades ago, glucagon‐like peptide‐1 receptor agonists rapidly
reshaped the field of Type 2 diabetes mellitus (T2DM) care by providing glycaemic control in …

There is a critical unmet need for therapeutics to treat the epidemic of comorbidities
associated with obesity and type 2 diabetes, ideally devoid of nausea/emesis. This study …

Summary Glucagon-like peptide-1 receptor (GLP-1R) agonists used to treat type 2 diabetes
mellitus often produce nausea, vomiting, and in some patients, undesired anorexia. Notably …

Aim To develop a conjugate of vitamin B12 bound to the glucagon‐like peptide‐1 receptor
(GLP‐1R) agonist exendin‐4 (Ex4) that shows reduced penetrance into the central nervous …

The use of glucagon-like peptide-1 (7–36) amide (GLP-1) receptor agonists for the treatment
of type 2 diabetes mellitus is commonly associated with nausea and vomiting. Therefore, the …

The use of glucagon-like peptide-1 (7–36) amide (GLP-1) receptor agonists for the treatment
of type 2 diabetes mellitus is commonly associated with nausea and vomiting. Previous …

Background Rodents are incapable of emesis and consequently the emetic potential of
glucagon-like peptide-1 receptor (GLP-1R) agonists in studies designed to assess a …

Background GLP-1 receptor agonists are utilised for the treatment of Type-2 diabetes but
can be associated with undesirable effects of nausea and vomiting. Objectives To …

Corrination is the conjugation of a corrin ring containing molecule, such as vitamin B12
(B12) or B12 biosynthetic precursor dicyanocobinamide (Cbi), to small molecules, peptides …